Skip to Content

UK Edition. Click here for US version.


Active substance(s): OXALIPLATIN

View full screen / Print PDF » Download PDF ⇩

Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if
their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
In this leaflet:
What is and what it is used for
Before you use
How to use
Possible side effects
How to store
Further information
The active ingredient of is oxaliplatin.
is used to treat cancer of the large bowel (treatment of stage III colon cancer after
complete resection of primary tumour, metastatic cancer of colon and rectum). is
used in combination with other anticancer medicines called 5 fluorouracil and folinic acid.
has to be dissolved and made into a solution before it can be injected into a vein.
is an anticancer drug and contains platinum.
Do not use :
- if you are allergic (hypersensitive) to oxaliplatin or any other ingredient of < OXALIPLATINE>,
like lactose monohydrate;
- if you are breast-feeding;
- if you already have a reduced number of blood cells;
- if you already have tingling and numbness in the fingers and/or toes; and have difficulty performing
delicate tasks, such as buttoning clothes;
- if you have a severe kidney problem.
Take special care with :
• If you have ever suffered an allergic reaction to platinum-containing medicines such as carboplatin,
• If you have moderate kidney problems,
• If you have any liver problems,
Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines,
including medicines obtained without a prescription.
Pregnancy and breast-feeding

You must not use oxaliplatin during pregnancy unless clearly indicated by your doctor
You must not become pregnant during treatment with oxaliplatin and you must use an effective
method of contraception.
If you get pregnant during your treatment, you must immediately inform your doctor. You should take
appropriate contraceptive measures during and after cessation of therapy continuing for 4 months for
women and 6 months for men.
Oxaliplatin may have an anti-fertility effect, which could be irreversible. Male patients are therefore
advised not to father a child during and up to 6 months after treatment and to seek advice on
conservation of sperm prior to treatment.
You must not breast-feed while you are treated with oxaliplatin.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Oxaliplatin treatment may result in an increased risk of dizziness, nausea and vomiting, and other
nervous symptoms that affect gait (difficulty walking or moving) and balance (ability to stay upright
or dizziness upon standing). If this happens you should not drive or operate machinery.
If you have vision problems while taking Oxaliplatin Mylan, do not drive, operate heavy machines, or
engage in dangerous activities.
is intended for adults only.
The dose of oxaliplatin is based on your body surface area. This is calculated from your height and
The usual dose for adults including the elderly is 85 mg/m² of body surface area. The dose you receive
will also depend on the results of your blood test and whether you have previously experienced side
effects with oxaliplatin.
Method and route of administration
will be prescribed for you by a specialist in cancer treatment.
You will be treated by a healthcare professional who will have made up the required dose of
This medicine is given by slow injection into one of your veins (an intravenous infusion) over a 2- to
6-hour period.
This medicine will be given to you at the same time as folinic acid and before the infusion of 5
Frequency of administration
It is determined by your doctor. For information, infusions should be repeated once every two weeks.
Duration of treatment
It is determined by your doctor.
Your treatment will last a maximum of 6 months when used after complete resection of your tumour.
If you are given more than you should be given:
As this medicine is given in a hospital, it is unlikely that you will be given too little or too much,
however tell your doctor or pharmacist if you have any concerns.
In case of overdose, you may experience an increase in side effects. Your doctor may give you
appropriate treatment for these side effects.
If you have any questions about your treatment, ask your doctor, nurse or your pharmacist.

Like all medicines, can cause side effects, although not everybody gets them.
If you experience any side effect it is important that you inform your doctor before your next
Tell your doctor immediately if you notice any of the following:
- Abnormal bruising, bleeding or signs of infection such as a sore throat and high temperature;
- Persistent or severe diarrhoea or vomiting;
- Stomatitis/mucositis (sore lips or mouth ulcers);
- Unexplained respiratory symptoms such as a non-productive cough, difficulty in breathing or
- Symptoms of angioedema (swelling of the hands or feet or ankles or face or lips or mouth or throat)
which may cause difficulty in swallowing or breathing.
The very common side effects (occurs in more than 1 in 10 users) are:
- A disorder of the nerves, which can cause weakness, tingling or numbness in the fingers, toes,
around the mouth or in the throat that may sometimes occur in association with cramps. This is often
triggered by exposure to the cold, e.g. opening a refrigerator or holding a cold drink. You may also
have difficulty in performing delicate tasks, such as buttoning clothes. Although in the majority of
cases these symptoms disappear completely, there is a possibility of persistent symptoms after the end
of the treatment;
- Some people have experienced a tingling, shock-like sensation passing down their arms or trunk
when the neck is flexed;
- Oxaliplatin can sometimes cause an unpleasant sensation in the throat, in particular when
swallowing, and give the sensation of shortness of breath. This sensation, if it happens, usually occurs
during or within hours of the infusion and may be triggered by exposure to the cold. Although
unpleasant, it will not last long and goes away without the need for any treatment. Your doctor may
decide to alter your treatment as a result;
- Signs of infection such as a sore throat and high temperature;
- This medicine causes temporary reduction in the number of blood cells. Reduction in the number of
white blood cells, which make infections more likely; Reduction in blood platelets, which increases
the risk of bleeding or bruising; Reduction in red blood cells, which can make the skin pale and cause
weakness or breathlessness.
Your doctor will take blood to check that you have sufficient blood cells before you start treatment
and before each subsequent course;
- Allergic reactions sometimes fatal - skin rash including red itchy skin, swelling of the hands, feet,
ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing) and you
may feel you are going to faint, bronchospasm, sensation of chest pain,
- Loss or lack of appetite;
- Excessive levels of glucose (sugar) in your blood which may cause a great thirst, dry mouth or a need
to urinate more often;
- Low blood levels of potassium which can cause abnormal heart rhythm;
- Low blood levels of sodium which can cause tiredness and confusion, muscle twitching, fits or coma;
- Taste disorder;
- Headache;
- Nosebleeds;
- Shortness of breath;
- Coughing;
- Nausea (feeling sick), vomiting (being sick) - medication to prevent sickness is usually given to you
by your doctor before treatment and may be continued after treatment;
- Diarrhoea - if you suffer from persistent or severe diarrhoea or vomiting contact your doctor
immediately for advice;
- Sore mouth or lips, mouth ulcers;
- Stomach pain, constipation;
- Skin disorder;

- Hair loss;
- Back pain;
- Tiredness, loss of strength/weakness, body pain;
- Pain or redness close to or at the injection site during the infusion which can lead to necrosis (death
of cells and living tissue) in case of extravasation (leakage of blood);
- Fever with possible involuntary movements of the hand or other member;
- Blood tests which show changes in the way the liver is working;
- Blood tests which show increase in lactate deshydrogenase (enzyme);
- Gain of weight;
Common side effects (occurs in less than 1 in 10 users) are:
- Runny nose;
- Chest infection;
- Infection due to a reduction in white blood cells, septicaemia;
- Anaphylactic shock or severe allergic reaction (bronchospasm, oedema);
- Dehydration;
- Depression;
- Insomnia,
- Dizziness;
- Swelling of the nerves to your muscles;
- Neck stiffness, intolerance/dislike of bright light and headache;
- Conjunctivitis, visual problems;
- Abnormal bleeding;
- Blood clot, usually in a leg, which causes pain swelling or redness;
- Blood clot in the lungs which causes chest pain and breathlessness;
- Flushing;
- Hypertension;
- Hiccups;
- Indigestion and heartburn;
- Lower gastrointestinal and gastrointestinal bleeding,
- Flaking skin, skin rash, increased sweating and nail disorder;
- Joint pain and bone pain;
- Blood in the urine;
- Pain on passing urine or a change in frequency of passing urine;
- Blood tests which show changes in the way the kidney is working;
- Loss of weight;
Uncommon side effects (occurs in less than 1 in 100 users) are:
- Blood tests which show an increase in acidity;
- Feeling anxious or nervous;
- Hearing problems;
- Impaired or blocked bowel passage;
- Nervous symptoms including involuntary contractions of the muscles, sensation of compression of
the throat or chest, or symptoms that affect gait (difficulty walking or moving) and balance (ability to
stay upright or dizziness upon standing);
- Symptoms which show changes in the way the cranial nerve is working (eye and sight disorders,
speech and voice disorders, strong facial pain).
Rare side effects (occurs in less than 1 in 1,000 users) are:
- Reduction in blood platelet (deficiency of blood platelets with abnormal bruising and bleeding, with
the body being allergic to oxaliplatin);
- Abnormal reduction of red blood cells (anaemia as a result of excessive breakdown of the blood);
- Slurred speech;
- Visual problems such as reduction of keenness/sharpness of perception or visual field, transient
vision loss reversible following therapy discontinuation;

- Inflammation of the optic nerve;
- Deafness (hearing impairment);
- Unexplained respiratory symptoms, difficulties in breathing, scarring of the lungs which causes
shortness of breath, sometimes fatal;
- Inflammation of the large bowel which causes abdominal pain or diarrhoea;
Very rare side effects (occurs in less than 1 in 10,000 users) are:
- Liver disease that your doctor will monitor you for;
- Changes in kidney function, acute kidney disorders;
- Inflammation of the pancreas.
Frequency unknown:
Some cases of convulsion (uncontrolled shaking of the body), haemolytic uremic syndrome

(kidney disorders associated with blood disorders) and leukoencephalopathy (neurological
disorders) have been reported.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
Keep out of the reach and sight of children.
No special precaution for storage for the unopened vials.
Do not use after the expiry date which is stated on the carton or vial.
When the infusion has finished, the medicine will be disposed of carefully by the doctor or nurse.
What contains
- The active substance is: oxaliplatin.
- The other ingredient is: lactose monohydrate.
What looks like and contents of the pack:
This medicine is in the form of a powder for solution for infusion.
50 mg vial: each 30 ml vial contains 50 mg oxaliplatin for reconstitution in 10 ml of solvent.
100 mg vial: each 50 ml vial contains 100 mg oxaliplatin for reconstitution in 20 ml of solvent.
One ml of reconstituted solution contains 5 mg of oxaliplatin.
Vial of 50mg or 100mg of powder. Pack of 1, 2, 3, 5, 10 or 50 vials.
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
< to be completed nationally>
VIANEX S.A., Plant C, 16 th km Marathonos Avenue, 153 51 Pallini Attiki, GREECE
MYLAN S.A.S, 117 allée des Parcs – 69800 SAINT-PRIEST, FRANCE
This leaflet was last approved in 07/2009.

The following information is intended for medical or healthcare professionals only:
As with other potentially toxic compounds, caution should be exercised when handling and preparing
oxaliplatin solutions.
1. Instructions for Handling
The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee
the protection of the handler and his surroundings.
The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist
personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the
medicinal product, the protection of the environment and in particular the protection of the personnel
handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved
for this purpose. It is forbidden to smoke, eat or drink in this area.
Personnel must be provided with appropriate handling materials, notably long sleeved gowns,
protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work
area, containers and collection bags for waste.
Excreta and vomit must be handled with care.
Pregnant women must be warned to avoid handling cytotoxic agents.
Any broken container must be treated with the same precautions and considered as contaminated
waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below
chapter “Disposal”.
If oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with
skin, wash immediately and thoroughly with water.
If oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with
mucous membranes, wash immediately and thoroughly with water.
2. Special precautions for administration
- DO NOT use injection equipment containing aluminium.
- DO NOT administer undiluted.
- Only glucose 5 % (50 mg/ml) infusion solution is to be used as a diluent. DO NOT reconstitute or
dilute for infusion with sodium chloride or chloride containing solutions.
- DO NOT mix with any other medicinal products in the same infusion bag or administer
simultaneously by the same infusion line. DO NOT mix with alkaline medicinal products or solutions,
in particular 5-fluorouracil (5 FU), folinic acid (FA) preparations containing trometamol as an
excipient and trometamol salts of others active substances. Alkaline medicinal products or solutions
will adversely affect the stability of oxaliplatin.
Instruction for use with folinic acid (FA) (as calcium folinate or disodium folinate):
Oxaliplatin 85 mg/m2 intravenous infusion in 250 to 500 ml of glucose 5 % (50 mg/ml) solution is
given at the same time as folinic acid (FA) intravenous infusion in glucose 5 % (50 mg/ml) solution,
over 2 to 6 hours, using a Y-line placed immediately before the site of injection. These two medicinal
products should not be combined in the same infusion bag. Folinic acid (FA) must not contain
trometamol as an excipient and must only be diluted using isotonic glucose 5 % (50 mg/ml) solution,
never in alkaline solutions or sodium chloride solutions.
Instruction for use with 5 fluorouracil (5 FU):
Oxaliplatin should always be administred before fluoropyrimidines – i.e. 5 fluorouracil (5 FU).
After oxaliplatin administration, flush the line and then administer 5 fluorouracil (5 FU).
- USE ONLY the recommended solvents.

- Any reconstituted solution that shows evidence of precipitation should not be used and should be
destroyed with due regard to legal requirements for disposal of hazardous waste.
3. -Preparation of the reconstituted solution (5 mg oxaliplatin/ml)
- Water for injections or glucose 5% (50 mg/ml) solution should be used to reconstitute the solution.
- For a vial of 50 mg: add 10 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.
- For a vial of 100 mg: add 20 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.
From a microbiological and chemical point of view, the reconstituted solution should be diluted
immediately with glucose 5 % (50 mg/ml) solution.
Inspect visually prior to use. Only clear solutions without particles should be used.
The medicinal product is for single use only. Any unused solution should be discarded.
4.Preparation of the infusion solution
Withdraw the required amount of reconstituted solution from the vials and then dilute with 250 to 500
ml of a glucose 5 % (50 mg/ml) solution to give an oxaliplatin concentration between not less than 0.2
mg/ml and 0.7 mg/ml.
Administer by intravenous infusion.
After dilution in glucose 5 % (50 mg/ml) solution, chemical and physical in-use stability has been
demonstrated for 48 hours at 2 °C to 8 °C.
From a microbiological point of view, the infusion preparation should be used immediately.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the
user and would normally not be longer than 24 hours at 2 °C to 8 °C unless dilution has been taken
place in controlled and validated aseptic conditions.
Inspect visually priori to use. Only clear solutions without particles should be used.
The medicinal product is for single use only. Any unused infusion solution should be discarded (see
chapter “Disposal” below).
NEVER use sodium chloride solutions for either reconstitution or dilution.
The compatibility of oxaliplatin solution for infusion has been tested with representative, PVC-based,
administration sets.
5. Infusion of the solution
The administration of oxaliplatin does not require prehydration.
Oxaliplatin diluted in 250 to 500 ml of a glucose 5 % (50 mg/ml) solution to give a concentration not
less than 0.2 mg/ml must be infused either by peripheral vein or central venous line over 2 to 6 hours.
When oxaliplatin is administered with 5 fluorouracil (5 FU), the oxaliplatin infusion must precede the
administration of 5 fluorouracil (5 FU).
6. Disposal
Remnants of the medicinal product as well as all materials that have been used for reconstitution, for
dilution and administration must be destroyed according to hospital standard procedures applicable to
cytotoxic agents and with due regard to current laws related to the disposal of hazardous waste.

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.